Novartis acquires UK biotech Myricx for up to $1.5 billion in pursuit of a new class of cancer drugs.

      Novartis has made a deal to acquire Myricx Bio, a small British oncology firm, for as much as $1.5 billion, enhancing its cancer pipeline with a promising yet early-stage technology as the industry competes to innovate. The Swiss company will provide $1.1 billion upfront, with up to an additional $400 million contingent on achieving specific milestones. This acquisition aligns with a trend among major pharmaceutical firms that are looking to European biotech for the next wave of targeted treatments, representing a gamble on scientific advancements that have yet to benefit patients.

      Myricx is relatively unknown, which is understandable, as it is still in the pre-clinical phase, meaning its leading programs have not yet entered human trials. The company is developing a new payload for antibody-drug conjugates (ADCs), a category of drugs that is becoming increasingly competitive in oncology. ADCs function like precision-guided weapons, utilizing an antibody to transport a toxic drug directly to cancer cells, and Myricx's proposal involves a novel type of warhead.

      The specific chemistry may be complex, as Myricx is focused on N-myristoyltransferase inhibitors, or NMTi, as the toxic part of its conjugates. The company believes this strategy can overcome the resistance and toxicity challenges that many current ADCs face. Its two primary assets target B7-H3 and HER2, both linked to various solid tumors, which are areas where the clinical and commercial stakes are notably high.

      For Novartis, this approach is well-reasoned. Large pharmaceutical companies increasingly see their own labs as just one source of innovation and seek to acquire others, especially in rapidly evolving fields where smaller, specialized teams might already be ahead of the curve. Investment in ADCs has surged across the industry, and having a unique payload platform is deemed more valuable than merely replicating an existing drug.

      The timing of this deal coincides with a period where the lines between biology and computational science are merging, attracting significant investment. In the first quarter of 2026 alone, AI-driven drug discovery garnered billions, marking a trend in biotech acquisitions, including those involving European AI initiatives.

      Although Myricx relies on traditional medicinal chemistry rather than machine learning, it is part of the broader movement towards innovative therapeutic approaches. Its investors include Brandon Capital and Novo Holdings, which is associated with the Danish pharmaceutical sector. The sale represents a valuable exit for venture capitalists in biotech.

      Acquiring a pre-clinical company for up to $1.5 billion is a notable outcome, despite the final amount depending on milestones that may not be met. This acquisition is also significant for British life sciences, which offers strong early-stage research but often sees its most promising firms acquired by larger foreign companies before they reach maturity.

      Myricx originated from academic research and was funded by venture capital, and its sale to a Swiss corporation follows a recognized pattern that benefits founders and investors while resulting in value creation occurring outside the UK. This trend has sparked ongoing discussions concerning UK industrial policy.

      It's important to note that while the initial $1.1 billion is a significant sum, the additional $400 million is conditional on successful scientific outcomes, and pre-clinical projects are known to fail more frequently than they succeed. Novartis is essentially acquiring potential rather than a completed product, with the deal's true value dependent on clinical results that are still years away. The companies anticipate finalizing the transaction in the latter half of 2026.

      Ultimately, this acquisition reflects less about any individual molecule and more about the direction major companies are aiming for. The straightforward targets in oncology have largely been addressed, and the new frontier focuses on more sophisticated delivery systems, enhanced payloads, and combinations that protect healthy tissue. Novartis has concluded that a small British team may hold one of the solutions, prompting them to invest in exploring this potential.